Results 121 to 130 of about 4,805 (202)

Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. [PDF]

Clin Epigenetics
Lin J, Zhuang X, Jia S, Zhou H, Qin D, Zhou J, Chen B, Zhuang M, Xu B, Zha J.   +9 more
europepmc   +1 more source

A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition. [PDF]

Transl Lung Cancer Res
von Itzstein MS, Gerber DE.
europepmc   +1 more source

Dexamethasone/Selinexor Regimen [PDF]

, 2020
openaire   +1 more source

Selinexor for multiple myeloma

Australian Prescriber, 2022
openaire   +2 more sources

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]

Ann Med
Tan S, Li Y, Cao Y, Sun W, Hui W.
europepmc   +1 more source

Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Am J Cancer Res
Jiang S, Li Y, Liu C, Liu Y, Zhang Q, Lv F, Zhang W.   +6 more
europepmc   +1 more source

XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]

Cell Commun Signal
Xu TT, Cai MC, Cheng S, Huang YH, Zhang QQ, Xu PP, Wang L, Qiu YR, Zhao WL.   +8 more
europepmc   +1 more source

Erratum: <i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]

Transl Lung Cancer Res
Editorial Office.
europepmc   +1 more source

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration. [PDF]

Front Immunol
Feng X, Ding Y, Huang Y, Qin H, Wang X, Zeng Y.   +5 more
europepmc   +1 more source

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. [PDF]

Cells
Di Marco MV, Gasparetto A, Chiarle R, Voena C.   +3 more
europepmc   +1 more source